<DOC>
	<DOCNO>NCT00074074</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , infliximab , locate tumor cell either kill deliver tumor-killing substance without harm normal cell . PURPOSE : Randomized phase II trial study effectiveness infliximab treat patient myelodysplastic syndrome .</brief_summary>
	<brief_title>Infliximab Treating Patients With Myelodysplastic Syndrome</brief_title>
	<detailed_description>OBJECTIVES : - Determine therapeutic activity 2 different dos infliximab peripheral blood cell count peripheral bone marrow blast cell count patient low- intermediate-risk myelodysplastic syndrome . - Determine subjective objective toxicity regimens patient . - Determine response rate ( complete partial response hematological improvement ) patient treat regimen . - Determine duration response patient treat regimen . OUTLINE : This randomize , open-label , multicenter study . Patients stratify accord cytogenetics ( good v intermediate v unknown due failure ) , overall International Prognostic Scoring System score ( low [ 0 ] v intermediate 1 [ 0.5-1.0 ] v intermediate 2 [ 1.5-2.0 ] ) , participate center . Patients randomize 1 2 treatment arm . - Arm I : Patients receive infliximab IV day 1 , 15 , 43 , 71 , 99 , 127 , 155 , 183 absence disease progression unacceptable toxicity . - Arm II : Patients receive high dose infliximab arm I . Patients achieve response ( complete partial response hematological improvement ) continue therapy beyond day 183 absence disease progression . Patients follow 2 week every 3 month thereafter . PROJECTED ACCRUAL : A total 80 patient ( 40 per treatment arm ) accrue study within 2 year .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Confirmed diagnosis ( within past month ) low intermediaterisk myelodysplastic syndrome ( MDS ) meeting follow criterion : No 10 % bone marrow blast ( correspond refractory anemia [ RA ] , RA ring sideroblast , RA excess blast ) Meets least 1 follow hematopoietic criterion : Hemoglobin great 10 g/dL OR red blood cell transfusion dependent Neutrophil count great 1,500/mm^3 Platelet count great 100,000/mm^3 OR platelet transfusion dependent No poor cytogenetics ( complex abnormality involvement chromosome 7 ) Patients unknown cytogenetics may eligible provide reasonable effort make determine cytogenetic profile result consider failure ( e.g. , normal karyotype [ NN ] 10 metaphase ) PATIENT CHARACTERISTICS : Age 18 Performance status WHO 02 Life expectancy Not specify Hematopoietic See Disease Characteristics Hepatic No history document hepatitis C No document active hepatitis B Bilirubin great 1.5 time upper limit normal ( ULN ) ALT le 2.5 time ULN Renal Creatinine less 1.5 time ULN Cardiovascular No New York Heart Association class III IV heart disease No clinical history evidence congestive heart failure No severe cardiac dysfunction LVEF great 35 % Pulmonary No prior concurrent active latent tuberculosis ( TB ) No evidence prior concurrent active TB ( i.e. , fibrotic pleural scarring , pulmonary nodule , mediastinal and/or hilar lymphadenopathy , upper lobe volume loss , cavitation ) chest xray Negative intradermal tuberculin skin test ( i.e. , induration le 5 mm ) No severe pulmonary dysfunction Immunologic No prior concurrent opportunistic infection ( e.g. , herpes zoster , cytomegalovirus , Pneumocystic carinii , aspergillosis , histoplasmosis , mycobacteria TB ) within past 6 month No concurrent severe ( CTC grade III IV ) active , chronic , recurrent infection No recent history allergy HIV negative Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 6 month study participation No prior clinically significant adverse event murine chimeric protein human/murine recombinant product No recent contact individual active TB No poor medical risk due systemic disease No multiple sclerosis demyelinate disorder No peripheral neuropathy great CTC grade 1 No malignancy within past 5 year except adequately treat carcinoma situ cervix nonmelanoma skin cancer No psychological , familial , sociological , geographical condition would preclude study compliance PRIOR CONCURRENT THERAPY : Biologic therapy No prior infliximab monoclonal antibody At least 6 week since prior hematopoietic growth factor MDS At least 3 month since prior therapy target reduce tumor necrosis factor ( TNF ) alpha ( e.g. , pentoxifylline , thalidomide , etanercept ) No concurrent epoetin alfa , filgrastim ( GCSF ) , sargramostim ( GMCSF ) No concurrent drug target reduce TNF alpha ( e.g. , pentoxifylline , thalidomide , etanercept ) Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy Not specify Surgery No prior solid organ transplantation Corneal transplantation 3 month ago allow Other No prior randomization clinical trial At least 6 week since prior treatment MDS ( except supportive care ) No concurrent investigational agent No concurrent anticancer therapy No concurrent therapeuticdose nonsteroidal antiinflammatory drug ( NSAIDs ) Concurrent sporadic ( 3 tablets/week ) overthecounter NSAIDs allow Concurrent cardioprotective dos ( 80 mg/day equivalent ) aspirin allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia ring sideroblast</keyword>
	<keyword>refractory anemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
</DOC>